Dendreon Corp.'s Provenge drug for treating prostate cancer has been shifted by the FDA to a panel of experts on cell and gene therapies, raising questions about its ultimate approval. Provenge, which seeks clearance for treating men for whom hormone therapies failed, works by stimulating the immune system to attack the cancer.

Full Story:

Related Summaries